FDA Recommends Separate Manufacturing For Sensitizing Non-Penicillin Beta-Lactams
This article was originally published in The Pink Sheet Daily
In comments on the draft guidance, though, some firms want clearer strictures from the agency, while others seek more flexibility.
You may also be interested in...
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.